{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:56:20Z","timestamp":1793894180564,"version":"4.8.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.xphs.2021.08.037","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T01:34:22Z","timestamp":1631496862000},"page":"3963-3968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparative Bioavailability of Two Formulations of Biopharmaceutical Classification System (BCS) Class IV Drugs: A Case Study of Lopinavir\/Ritonavir"],"prefix":"10.1016","volume":"110","author":[{"given":"Ahmed M.","family":"Saeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery M.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wijith P.","family":"Munasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhadrish K.","family":"Vallabh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nael M.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2021.08.037_bib0001","unstructured":"UNAIDS. UNAIDS data 2019. Available at: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2019-UNAIDS-data_en.pdf. Accessed March 8, 2021."},{"key":"10.1016\/j.xphs.2021.08.037_bib0002","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2021.08.037_bib0003","series-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach","year":"2016"},{"key":"10.1016\/j.xphs.2021.08.037_bib0004","series-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach","year":"2013"},{"key":"10.1016\/j.xphs.2021.08.037_bib0005","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3389\/fphar.2018.00890","article-title":"Assessing the Efficacy of Lopinavir\/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations","volume":"9","author":"Huang","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.xphs.2021.08.037_bib0006","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","volume":"381","author":"Boyd","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.xphs.2021.08.037_bib0007","unstructured":"Kaletra prescribing information. 2016. Available at: https:\/\/www.rxabbvie.com\/pdf\/kaletratabpi.pdf. Accessed October 8, 2021."},{"key":"10.1016\/j.xphs.2021.08.037_bib0008","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3018(17)30109-1","article-title":"Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV\/AIDS: a systematic review and network meta-analysis","volume":"4","author":"Kanters","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.xphs.2021.08.037_bib0009","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jpba.2010.04.012","article-title":"Peter H\u00f6ligd, et\u00a0al. In situ formation of nanoparticles upon dispersion of melt extrudate formulations in aqueous medium assessed by asymmetrical flow field-flow fractionation","volume":"53","author":"Kanzera","year":"2010","journal-title":"J Pharmaceut Biomed Anal"},{"key":"10.1016\/j.xphs.2021.08.037_bib0010","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/jac\/dkq468","article-title":"Pharmacokinetics of plasma lopinavir\/ritonavir following the administration of 400\/100 mg, 200\/150 mg and 200\/50 mg twice daily in HIV-negative volunteers","volume":"66","author":"Jackson","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2021.08.037_bib0011","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/17425247.2011.606808","article-title":"Oral formulation strategies to improve solubility of poorly water-soluble drugs","volume":"8","author":"Singh","year":"2011","journal-title":"Exp Opin Drug Del"},{"key":"10.1016\/j.xphs.2021.08.037_bib0012","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jac\/dkp472","article-title":"Pharmacokinetics of two generic co-formulations of lopinavir\/ritonavir for HIV-infected children: a pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers","volume":"65","author":"de Kanter","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2021.08.037_bib0013","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/jps.22048","article-title":"Bioavailability of generic ritonavir and lopinavir\/ritonavir tablet products in a dog model","volume":"99","author":"Garren","year":"2010","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.xphs.2021.08.037_bib0014","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/jps.22048","article-title":"Bioavailability of Generic Ritonavir and Lopinavir\/Ritonavir Tablet Products in a Dog Model","volume":"99","author":"Garren","year":"2010","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.xphs.2021.08.037_bib0015","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jps.21859","article-title":"Re: Acknowledgement of human bioequivalency of matrix's lopinavir\u2013ritonavir formulation to Kaletra, Comment to article on bioavailability of generic ritonavir and lopinavir\/ritonavir tablet products in a dog model, by Garren et\u00a0al","volume":"99","author":"Rackley","year":"2010","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.xphs.2021.08.037_bib0016","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/jps.21852","article-title":"Response to the Comparison of generic ritonavir (Ritomune, Cipla) and lopinavir\/ritonavir tablets (Lopimune, Cipla) and the Abbott brand (Norvir Soft-Gel Capsules and Kaletra Tablets)","volume":"99","author":"Chachad","year":"2010","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.xphs.2021.08.037_bib0017","unstructured":"Kalidavir. Patient Information Leaflet. JSC Pharmasyntez, INN 3810023308. 2018."},{"key":"10.1016\/j.xphs.2021.08.037_bib0018","unstructured":"U.S. Food and Drug Administration, Center for Evaluation and Research. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. 2001. Available at: https:\/\/www.fda.gov\/media\/70958\/download. Accessed March 8, 2021."},{"key":"10.1016\/j.xphs.2021.08.037_bib0019","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs \u2013 General Considerations. 2014. Available at: https:\/\/www.fda.gov\/media\/88254\/download. Accessed March 8, 2021."},{"key":"10.1016\/j.xphs.2021.08.037_bib0020","unstructured":"European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. 2010. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed March 8, 2021."},{"key":"10.1016\/j.xphs.2021.08.037_bib0021","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s11094-020-02130-0","article-title":"Molecular-biological problems of drug design and mechanism of drug action: Planning and evaluation of bioequivalence studies of lopinavir\/ritonavir preparations","volume":"53","author":"Uvarova","year":"2020","journal-title":"Pharmaceut Chem J"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921004585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921004585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:36:52Z","timestamp":1758361012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921004585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0022354921004585"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.08.037","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Bioavailability of Two Formulations of Biopharmaceutical Classification System (BCS) Class IV Drugs: A Case Study of Lopinavir\/Ritonavir","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.08.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}